-continued

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

- 34. A pharmaceutical composition comprising a compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, and optionally a pharmaceutically acceptable excipient.
- 35. The pharmaceutical composition of claim 34, wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound for use in treating a proliferative disease in a subject in need thereof.
- 36. A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 34 or 35.
- 37. The method of claim 36, wherein the disease is a proliferative disease, a metabolic disorder, autoimmune disease, or a neurological disease.
- 38. The method of claim 36, wherein the proliferative disease is cancer.
- 39. The method of claim 38, wherein the cancer is a carcinoma.
- 40. The method of claim 38, wherein the cancer is lung cancer.
- 41. The method of claim 40, wherein the lung cancer is non small-cell lung cancer.
- 42. The method of claim 38, wherein the cancer is breast cancer.

- 43. The method of claim 38, wherein the cancer is liver cancer.
- 44. The method of claim 38, wherein the cancer is pancreatic cancer.
- 45. The method of claim 38, wherein the cancer is gastric
- 46. The method of claim 38, wherein the cancer is ovarian cancer.
- 47. The method of claim 38, wherein the cancer is colon
- 48. The method of claim 38, wherein the cancer is colorectal cancer.
- 49. The method of claim 38, wherein the metabolic disorder is diabetes.
- 50. The method of claim 36, wherein the neurological disease is Alzheimer's disease.
- 51. The method of claim 36, wherein the neurological disease is gliosis.
- 52. The method of claim 36, wherein the neurological disease is spinal cord injury.
- 53. A method of male contraception in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 34 or 35.
- 54. The method of claim 53, wherein the male contraception comprises reducing or inhibiting spermatogenesis in a healthy fertile male subject.